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Epidermal growth factor receptor, p16, cyclin D1, and p53 staining paerns
for inverted papilloma
Giant C. Lin, MD, Adam Scheel, MD, Sarah Akkina, BS, Steven Chinn, MD, Martin Graham, BS,
Christine Komarck, BS, Heather Walline, MS, Jonathan B. McHugh, MD, Mark E. Prince, MD,
Thomas E Carey, PhD and Mark A. Zacharek, MD
Background: The aim of this study was beer character-
ize the staining paerns of inverted papilloma (IP) with and
without carcinoma by performing immunohistochemistry
for p16, epidermal growth factor receptor (EGFR), p53, and
cyclin D1 antibodies in a large patient cohort.
Methods: A total of 162 IP specimens were collected from
147 patients treated at the University of Michigan between
1996 and 2011. Twenty-two specimens contained carcinoma.
Tumor was extracted for construction of 2 tissue microar-
rays and stained for p16, EGFR, p53, and cyclin D1. Tumor
staining intensity and percentage staining were scored.
Results: Benign disease was positive for p16 in 64%, EGFR
in 50%, p53 in 30%, and cyclin D1 in 76%. IP with carcinoma-
tous degeneration was positive for p16 in 14%, EGFR in 71%,
p53 in 62%, and cyclin D1 in 76%. The diﬀerences in staining
positivity between benign and malignant disease reached
signiﬁcance for p16 and p53 only. Mean percentage staining
by tumor surface area for IP and IP with carcinoma was 12%
vs 7% for p16 (no statistical signiﬁcance [NS]), 20% vs 34%
for EGFR (NS), 4% vs 24% for p53 (p < 0.001), and 17% vs
21% for cyclin D1 (NS).
Conclusion: Important characteristic staining paern for
IP with and without carcinoma are highlighted in this study.
Unlike recent trends in human papilloma virus (HPV)-
related head and neck malignancies, low expression of
p16 is a marker for malignancy in this series. Positive stain-
ing for p53 correlates with the development of carcinoma
in IP. C© 2013 ARS-AAOA, LLC.
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I nverted papillomas (IPs) of the sinonasal tract remaina topic of controversy among surgeons and patholo-
gists with respect to etiology, pathogenesis, and biolog-
ical behavior. Representing between 0.4% and 4.7% of
all sinonasal neoplasms, the overall incidence of these tu-
mors is between 0.74 and 1.5 cases per 100,000 persons
per year.1,2 Risk factors for developing IP include out-
door and industrial occupation; smoking and other inflam-
matory diseases such as allergic rhinitis and sinusitis are
not considered etiologic factors.3 These tumors are known
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to degenerate into or simultaneously harbor carcinoma in
some patients, oftentimes with aggressive growth patterns
and intracranial or orbital extension that require radical re-
section. The current literature suggests a rate of malignancy
of 5% to 27%,4,5 with an average of 10%.6,7 Surgery re-
mains the mainstay for treatment of IP, and recurrence rates
remains significant, with a literature reported rate of 5.7%
to 32%.8–10
Perhaps secondary to its histologic appearance of hyper-
plastic Schneiderian mucosa enclosed in basement mem-
brane that grows endophytically into the underlying
stroma, the human papillomavirus (HPV) has been impli-
cated in the development of IP.11–15 However, definitive and
objective data supporting this association remains sparse,
and the true role of HPV in the pathogenesis of IP remains
controversial. Detection rates for HPV vary widely in the
literature, ranging from 0% to 72%, with an average of
about 25%.1,11 Surrogate markers of HPV have been stud-
ied even less exhaustively, and no universally accepted im-
munohistochemical markers currently exist for this disease.
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The retinoblastoma protein (pRB)/p16INK4a (p16) regu-
latory pathway is disrupted with HPV infection and is thus
a good candidate for study in the pathogenesis of IP. The
protein p16 functions as a cyclin-dependent kinase inhibitor
that shuts down cyclin D1-dependent phosphorylation of
the pRB, allowing dephosphorylation of pRb and cessation
of cell cycle progression at the G1 to S checkpoint. The
retinoblastoma protein in its dephosphorylated state binds
to the E2F family of transcription factors that upregulate
expression of proteins necessary for entry into the cell cy-
cle. When a cell is infected with high-risk HPV, the viral
E7 protein binds to and inactivates pRb, activating E2F
independently of cyclin-dependent kinase. The functional
inactivation of host pRb by the HPV E7 protein results in
overexpression of p16, making p16 a reasonable surrogate
marker for the presence of high-risk HPV.
Another host regulatory pathway disrupted by HPV in-
fection is cell-cycle control by the p53 tumor suppressor
protein. E6 protein from the HPV DNA genome inactivates
cellular regulatory protein p53 by associating with host
E6-associated protein and ubiquitinating host p53, mark-
ing this cell-cycle regulatory protein for degradation.16
This process allows for unregulated cellular proliferation
of epithelial cells and promotes oncogenesis. Epidermal
growth factor receptor (EGFR) can be similarly be overex-
pressed in HPV-infected cells secondary to the viral E5 gene
product.17
The purpose of this study was to better understand the
biology of IP by analyzing the staining pattern for p16,
EGFR, cyclin D1, and p53.
Materials and methods
The University of Michigan Institutional Review Board
(IRB) approved this study. Patients were identified from the
University of Michigan pathology archive, using the search
target “inverted papilloma” for exact matches. This study
required a stringent pathology review of all patient blocks
by dedicated head and neck pathologist (J.M.). To en-
sure consistency of pathology and patient reporting, other
Schneiderian papillomas such as fungiform papillomas and
cylindrical/oncocytic papillomas were excluded for data
analysis. We included any IP with or without dysplasia
or carcinomatous degeneration treated at the University of
Michigan between 1996 and 2011. A total of 162 IP speci-
mens from 122 patients treated at the University of Michi-
gan in the mentioned time period were studied. Charts were
reviewed for demographic data, follow-up duration, recur-
rence, and presence of malignancy.
A tissue microarray (TMA) was constructed to facilitate
the study of immunohistochemistry for p16, EGFR, p53,
and cyclin D1. The technique for TMA construction has
previously been methodically described,18 and the reader
is referred to this reference for details of construction.
Briefly, individual tumor blocks were cut and stained for
hematoxylin and eosin if corresponding slides for the tu-
mor block were not available from the pathology archives.
The area of tumor on each slide was marked, and the cor-
responding area of the tumor block was cored for TMA
construction.
For immunohistochemistry, TMA slides were deparaf-
finized and rehydrated. The antigen retrieval method var-
ied depending on the antibody used. For EGFR, pepsin was
used (Life Technologies, Carlsbad, CA); 10minutes at 37◦C
as per manufacture instructions. The standard citrate buffer
was used for p53 and cyclin D1 (25minutes at 92◦C, cooled
at room temperature for 25 minutes). For p16, CINtec
p16INK4a Histology kit (mtm laboratories, Westborough,
MA); kit instructions were followed. For all slides, peroxi-
dase was quenched with peroxidase block. All slides were
also blocked with casein for 30 minutes at room temper-
ature. Primary antibody, EGFR/31G7 (Life Technologies),
p53/D01 and cyclin D1/Clone SP4 (Thermo Scientific, Fre-
mont, CA), and p16 (CINtec p16INK4a Histology kit; mtm
laboratories, Westborough, MA) incubated for 1 hour and
probed with EnVision+System-HRP (DAKO Carpinteria,
CA) for p53, cyclin D1, and EGFR. For p16 the reagents
from the manufacturer’s kit were used (mtm laboratories).
Antibody binding was scored on a scale of 1 to 4 for
all antibodies: Grade 1 for less than 5% staining, grade
2 for 5% to 20%, grade 3 for 21% to 50%, and grade
4 for >50%. Intensity was scored as 1 for no staining, 2
for low intensity, 3 for moderate intensity, and 4 for high
intensity. Proportion and intensity of staining were scored
by a pathologist (J.B.M.) who was blinded to the clinical
outcome.
SPSS (IBM, Armonk, NY) version 19 was used for all sta-
tistical calculation and analysis. The product limit method
of Kaplan and Meier was used to calculate rates of lo-
cal regional control, overall survival, and disease-specific
survival.
Results
A total of 162 pathology blocks were available for study
from 147 patients, and this formed our study group
for immunohistochemical analysis. Twenty-two specimens
(13.6%) contained carcinoma. Among this study group,
111 patients were male. The cohort consisted of 112 Cau-
casian patients, 27 Black patients, 7 Asian patients, and 1
Hispanic patient.
p16
Eight samples were unsatisfactory for study, resulting in
154 total specimens; 104 of 154 (67.5%) showed some
degree of staining for p16, with an average stain area of
11.3% (Table 1). The staining pattern of p16 is nuclear and
cytoplasmic (Fig. 1). Benign disease was positive for p16 in
64% vs 14% for IP with carcinoma (p < 0.001) (Table 2).
Mean percentage staining for IP and IP with carcinoma
was 12% vs 7% for p16 (no statistical significance [NS])
(Table 3).
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TABLE 1. Overall stain results of all samples based on
intensity and percent staining
p16 EGFR p53 cyclin D1
Staining intensitya
No staining (I) 50 70 75 31
Weak staining (II) 0 13 0 33
Moderate staining (III) 14 39 1 27
Strong staining (IV) 90 34 80 66
Percent stainingb
Staining (I) 67 72 98 37
Staining (II) 63 29 42 66
Staining (III) 19 29 13 48
Staining (IV) 5 26 3 6
Average staining % 11.3 21.7 7.5 17.3
Total satisfactory samples 154 156 156 157
aStaining intensity (category I = no staining, category II = weak staining, category
III = moderate staining, and category IV = strong staining).
bPercent staining (category I = <5% staining, category II = 5% to 20% staining,
category III = 21% to 50% staining, and category IV for >50% staining).
EGFR = epidermal growth factor receptor.
EGFR
Six samples were unsatisfactory for study, resulting in 156
total specimens; 86 of 156 (55%) showed some degree of
staining for EGFR, with an average stain area of 21.7%
(Table 1). The staining pattern of EGFR is membranous
(Fig. 1). IP harboring malignancy stained positive for EGFR
in a higher percentage of specimens (71% vs 50%), but this
difference was not statistically significant (Table 2). The
mean percentage staining for IP and IP with carcinoma was
20% vs 34% (NS) (Table 3).
p53
Six samples were unsatisfactory for study, resulting in 156
total specimens; 81 of 156 (52%) showed some degree
of staining for p53, with an average stain area of 7.5%
(Table 1). The staining pattern of p53 is nuclear (Fig. 1).
Positive staining for p53 biomarker was found to be present
in 30% of benign specimens vs 62% in specimens harbor-
ing malignancy (p < 0.001) (Table 2). Mean percentage
staining for IP and IP with carcinoma was 4% vs 24%
(NS) (Table 3).
Cyclin D1
Five samples were unsatisfactory for study, resulting in 157
total specimens; 126 of 157 (80%) showed some degree of
FIGURE 1. Stain patterns for biomarkers used. (A) p16 staining is cytoplasmic and nuclear; this IP specimen was graded 4 for intensity and 90% staining
surface area. (B) EGFR staining is cytoplasmic; this IP specimen was graded 4 for intensity and 100% for staining surface area. (C) p53 staining nuclear; this IP
specimen harbors squamous cell carcinoma and was graded 4 for intensity and 100% for staining surface area. (D) Cyclin D1 staining is also nuclear; this IP
specimen was graded 3 for intensity and 30% for staining surface area. EGFR = epidermal growth factor receptor; IP = inverted papilloma.
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TABLE 2. Number and percentage positive staining for
p16, EGFR, p53, and cyclin D1 based on benign IP vs IP
with carcinogenesis
Benign IP IP with carcinoma Significance
p16+ (%) 85/133 (64%) 3/21 (14%) p < 0.001
EGFR+ (%) 68/135 (50%) 15/21 (71%) NS
p53+ (%) 45/135 (30%) 13/21 (62%) p < 0.001
Cyclin D1+ (%) 104/136 (76%) 16/21 (76%) NS
EGFR = epidermal growth factor receptor; IP = inverted papilloma; NS = not
statistically significant.
TABLE 3. Average stain percentage for p16, EGFR, p53,
and cyclin D1 for benign IP vs IP with carcinoma
Benign IP (%) IP with carcinoma (%) Significance
p16 12 7 NS
EGFR 20 34 NS
p53 4 24 p < 0.001
Cyclin D1 17 21 NS
EGFR = epidermal growth factor receptor; IP = inverted papilloma; NS = not
statistically significant.
staining for cyclin D1, with an average stain area of 17.3%
(Table 1). Similar to p53 staining, cyclin D1 staining is nu-
clear (Fig. 1). Specimens with IP only and specimens with
malignancy stained positive for cyclin D1 in 76% (NS)
(Table 2). Whereas the stain intensity for p16, EGFR, and
p53 for positive-stain specimens were almost all moderate
to strong, the stain intensity for cyclin D1–positive samples
varied widely. For cyclin D1, the mean percentage stain-
ing for IP and IP with carcinoma was 17% vs 21% (NS)
(Table 3).
Discussion
Characteristic staining patterns and reactivity are demon-
strated on a large cohort of patients in this study for p16,
EGFR, p53, and cyclin D1.Overall, p16 stainingwas signif-
icantly more likely to be positive for benign disease, while
p53 staining was more likely to be positive for IP with ma-
lignant degeneration. A higher percentage of IP specimens
with malignancy showed some degree of staining for EGFR
compared to benign IP, but this difference did not reach sta-
tistical difference. We did not find any difference in over-
all staining patterns between benign and malignant disease
for cyclin D1. However, it is noted that a significant por-
tion of both benign and malignant disease do demonstrate
immunoreactivity to cyclin D1 antibodies.
The literature is sparse on studies using p16 as a surrogate
marker for HPV detection for IP Allende et al.19 and Shah
et al.20 have investigated the use of p16 as amarker forHPV
presence in 2 separate studies, but these authors reported
contrasting results. Shah et al.20 reported that that 87.5%
of HPV-positive specimens by polymerase chain reaction
(PCR) were positive for p16, while 90.9% of HPV-negative
specimens also stained positive for p16. This study was
limited by a small patient population (n = 26 patients)
and used a combination of less sensitive PCR and biotinyl-
tyramide–based chromogenic in situ hybridization for HPV
detection. The high rate of p16 staining is opposite of the
report by Allende et al.,19 in which 4 of 7 IP were focally
positive for p16, 2 of 6 dysplastic lesions showed patchy
staining for p16, and 2 of 7 carcinomas were positive for
p16. Their study did not find HPV in any specimens.
Our study is the first to statistically analyze and demon-
strate a significantly higher degree of staining for p16 in IP
only compared to IP with malignancy. Our results suggest
that p16 expression is usually not lost during the develop-
ment of IP. In the process of carcinogenesis, the p16 gene
is more likely to be inactivated. This finding parallels non-
HPV–related head and neck cancer, in which loss of p16
expression is 1 of the most common oncogene alterations
secondary to loss of chromosomal region 9p21.21,22 The
progression to malignancy in IP may share similar path-
ways or gene alterations seen in the development of other
head and neck malignancies, but the exact mechanisms
require further study.
Because inactivation of retinoblastoma protein by high-
risk HPV E7 protein leads to p16 overexpression, p16
positivity is considered a useful surrogate marker for the
presence of high-risk HPV in head and neck cancer.23–25
The validity of p16 staining as evidence for HPV has not
been shown in IP. Although our current study does not
specifically address HPV presence directly via in situ hy-
bridization in PCR studies, the low average staining by
surface area for all IPs in this study (12% for benign dis-
ease and 7% for IP with carcinoma) is significantly less
than the diffuse positive staining seen in HPV-related head
and neck cancer.23,24,26–28 One study by Lewis et al.26 sug-
gests 75% staining as a suitable cutoff for defining HPV
positivity, and few of our specimens would meet this cri-
teria. At this time, it is not possible to delineate whether
the p16 staining detected in IP seen in the current study
is a HPV-related phenomenon or not. Because other fac-
tors such as abnormalities of the retinoblastoma protein or
deletion and methylation of the p16 locus can also lead to
p16 overexpression, p16 staining can be nonspecific.
EGFR is studied in our analysis because it can also be
altered by HPV infection. The E5 gene protein from HPV
DNA is a small hydrophobic protein consisting of 83 amino
acids that localizes to the cell membrane, Golgi appara-
tus, and endosome. E5 enhances the activation of EGFR
and its downstream signal transduction pathways, lead-
ing to increased mitogenic activity.17 Proposed mechanisms
for HPV E5 upregulation of EGFR include the EGFR-E5
protein complex, which affects EGFR activity, E5 inhi-
bition of endosome acidification, which inhibits degrada-
tion of endocytic EGFR, and E5 inhibition of trafficking
from early to late endosomes to delay EGFR degradation.
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Abnormal activation is seen in many epithelial malignan-
cies such as head and neck cancer, and is associated with
poorer outcomes.29–31 For IP, we found a trend for higher
EGFR staining for IP with malignant degeneration. The dif-
ference in EGFR staining between IP with carcinoma and
IP alone parallels what is seen in the development of epithe-
lial malignancies but did not reach statistical significance.
Chao et al.32 also reported a high percentage of EGFR stain-
ing in IP specimens and low staining in polyp and inferior
turbinate tissue, but the study did not perform statistical
calculation to assess these differences.
Last, this study suggests that p53 alteration is impor-
tant in the progression of IP to malignant disease. IP with
carcinoma stains positive for p53 at more than twice the
frequency of IP alone (62% vs 30%). Compared to the
low average percent stain by surface area in IP alone (4%),
samples with malignancy showed significantly higher per-
centage area of positive staining (24%). In a study of 30
patients with Schneiderian papillomas, including 3 patients
with either dysplasia or carcinoma, Mirza et al.13 found
30% of samples to be p53 positive by immunohistochem-
istry. Positive staining for p53 in this study correlated to
a 19% increase in the likelihood of malignancy at surgery.
The difference in p53 staining between benign and malig-
nant disease is higher in our cohort of patients. Franzmann
et al.33 also reported an overexpression of p53 in carcino-
mas occurring in sinonasal papillomas but not in the benign
tumors of the sinonasal mucosa. Staining for p53 is also low
for benign IP in a recent report by Sham et al.34 Our study
is congruent with these reports with respect to the close
relationship between p53 staining and malignancy.
Conclusion
Important characteristic staining patterns for IP with and
without carcinoma are highlighted in this study. The major-
ity of inverted papilloma without malignancy contain areas
of positive staining p16, and complete lost of expression of
this tumor suppressor protein is a marker for malignancy in
this series. This study also indicates that mutations in p53
likely play an important role in the process of malignant
degeneration.
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